764208 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.409 |
Oh Do-Youn, Ryu Min Hee, Hwang Jun-Eul, Cho Jaeyong, Zang Dae Young, Oh Sang Cheul, Lee Jeeyun, Lee Keun-Wook, Chung Hyun Cheol, Shim Byoung Yong, Chisamore Michael, Ho William, Rhee Paul, Won Ji Yeong, Kim Taewan, Baek Eunhye, Baek SeungJae |
764207 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
685 Characterization of molecular and spatial diversity of macrophages in hepatocellular carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.685 |
Hamon Pauline, Magen Assaf, Kim Joel, Buckup Mark, Troncoso Leanna, Hamel Steven, Berichel Jessica Le, Barboy Oren, David Eyal, Tabachnikova Alexandra, Chang Christie, Zhao Zhen, Cohen Merav, Giladi Amir, Malissen Nausicaa, Desland Fiona, Amit Ido, Kenigsberg Ephraim, Schwartz Myron, Marron Thomas, Merad Miriam |
764206 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
306 Decr2 regulates tumor cell ferroptosis and is required for immunotherapy efficacy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.306 |
Li Shuyin, Gajewski Thomas, Li Shuyin, Higgs Emily |
764205 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
713 Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model |
2021-11-01 |
10.1136/jitc-2021-sitc2021.713 |
Langley Emma, Li Chen, Zaid Jessica, Lee Tani-Ann, Yadav Deepak, Grot Brian, Singh Jay, Kim Johnovan |
764204 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
712 Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties |
2021-11-01 |
10.1136/jitc-2021-sitc2021.712 |
Jaekel Anika, Kehler Patrik, Lischke Timo, Goletz Christoph, Flechner Anke, Danielczyk Antje, Gellert Johanna |
764203 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion |
2021-11-01 |
10.1136/jitc-2021-sitc2021.711 |
Giffon Thierry, Desbois Melanie, Ng Dean, Yakkundi Poonam, Manlusoc Marigold, Oyasu Miho, Rosete Rodnie, Machado Daniel, Calhoun Susan, Kothambawala Tasnim, Saini Avneesh, Wang Beatrice, Kotturi Maya, Keyt Bruce, Sinclair Angus |
764202 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.710 |
Fousek Kristen, Horn Lucas, Qin Haiyan, Reddy Bobby, Sender Lennie, Shiong Patrick Soon, Schlom Jeffrey, Palena Claudia |
764201 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
709 Peptidyl IL-2/15Rβγc-restricted agonists, highly-attenuated and linked to anti-PD-1 antibodies to achieve selectivity and amplified potency in stimulating PD-1high lymphocytes |
2021-11-01 |
10.1136/jitc-2021-sitc2021.709 |
Dower William, Bakker Alice, Cwirla Steven, Williams Blake, Joshi Prarthana, Pongtornpipat Praechompoo, Needels Michael, Barrett Ronald |
764200 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
708 Novel ways to exploit IL-21 to augment adoptive T cell transfer therapy against tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.708 |
Cole Anna, RIvera Guillermo Rangel, Smith Aubrey, Wyatt Megan, Ware Brandon, Knochelmann Hannah, Paulos Chrystal |
764199 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
707 IL12 Fc-fusions engineered for reduced potency and extended half-life exhibit strong anti-tumor activity and improved therapeutic index compared to wild-type IL12 agents |
2021-11-01 |
10.1136/jitc-2021-sitc2021.707 |
Bernett Matthew, Liu Ke, Bonzon Christine, Hackett Michael, Bykova Katrina, Rashid Rumana, Rodriguez Nicole, Hassanzadeh-Kiabi Nargess, Ardila Connie, Barlow Norman, Leung Irene, Nguyen Hanh, Eivazi Araz, Avery Kendra, Varma Rajat, Muchhal Umesh, Desjarlais John |